NasdaqGS - Nasdaq Real Time Price USD

Enanta Pharmaceuticals, Inc. (ENTA)

Compare

5.10

+0.17

+(3.45%)

At close: April 17 at 4:00:02 PM EDT

5.10

0.00

(0.00%)

After hours: April 17 at 4:05:08 PM EDT

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Name	Title	Pay	Exercised	Year Born
Dr. Jay R. Luly Ph.D.	President, CEO & Director	1.23M	--	1956
Mr. Paul J. Mellett Jr.	Chief Financial & Administrative Officer	671.7k	--	1955
Dr. Yat Sun Or Ph.D.	Chief Scientific Officer	740.11k	--	1952
Mr. Matthew P. Kowalsky J.D.	Chief Legal Officer & Corporate Secretary	575.65k	--	1973
Dr. Scott T. Rottinghaus M.D.	Chief Medical Office	776.14k	43.48k	1974
Ms. Jennifer Viera	Executive Director of Investor Relations & Corporate Communications	--	--	--
Mr. Nathaniel S. Gardiner J.D.	Consultant	672.67k	49.14k	1954
Ms. Tara Lynn Kieffer Ph.D.	Chief Product Strategy Officer	496.85k	--	1978
Mr. Brendan Luu	Chief Business Officer	622.86k	--	1975

4 Kingsbury Avenue

Watertown, MA 02472

United States

617 607 0800 https://www.enanta.com

Sector:: Healthcare
Industry:
Full Time Employees:: 131

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 6. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

May 5, 2025 at 10:59 AM UTC - May 9, 2025 at 12:00 PM UTC

Enanta Pharmaceuticals, Inc. Earnings Date

March 17, 2025 at 12:00 AM UTC